Clinical trial · Observational
Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma
Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma: An Immunohistochemical Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Vitamin D has a crucial role in cancer control and prevention.vitamin D receptor (VDR) and its heterodimer Retinoid X receptor (RXR) are equally important in the cell. This ligand (vitamin D) and receptors (VDR-RXR) complex together triggers downstream DNA damage response in the cell. Retinoid receptors are a superfamily of nuclear receptors. The preferred receptor that attaches to VDR is RXR, with its subunits α, β and γ. RXR α is more frequent in the skin than other tissues, while β occurs in internal organs and γ is frequently related to neural disorders. the investigator hopes to assess prognosis of SCC \& BCC by using RXR-α biomarker \& attempts to use it in the treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-melanoma Skin Cancer | Skin Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma
- timeFrame
- One or two days after staining sections with the marker.
- description
- immuohistochemical expression of RXR-α in Squamous and Basal Cell Carcinoma
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Squamous cell carcinoma and basal cell carcinoma. 2. Incisional \& excisional biopsies. 3. All the studied cases include sufficient materials for the immunohistochemical study 4. Complete clinical data Exclusion Criteria: 1. Patients with a history of preoperative chemotherapy and/or radiotherapy. 2. Insufficient or tiny tissue biopsies.
References
Publications (0)
Data not yet available